Search Login Register

Porphyria Cutanea Tarda Summary

Description: An autosomal dominant or acquired porphyria due to a deficiency of UROPORPHYRINOGEN DECARBOXYLASE in the LIVER. It is characterized by photosensitivity and cutaneous lesions with little or no neurologic symptoms. Type I is the acquired form and is strongly associated with liver diseases and hepatic toxicities caused by alcohol or estrogenic steroids. Type II is the familial form.

Key Drugs and Agents for Porphyria Cutanea Tarda

Efficacy Chart >>
Drugs and Important Biological Agents (IBA) related to treatments:
  1. Chloroquine (Aralen) : 8 outcomes in 58 results : FDA 1 Generic
  2. Iron : 3 outcomes 8 studies in 106 results : IBA
  3. Hydroxychloroquine (Plaquenil) : 3 outcomes 1 study in 9 results : FDA 9 Generic
  4. Cimetidine (Biomet) : 3 outcomes in 3 results : FDA 57 Generic
  5. Uroporphyrinogen Decarboxylase (Uroporphyrinogen III Decarboxylase) : 2 outcomes 7 studies in 142 results : IBA
  6. Porphyrins : 2 outcomes 2 studies in 74 results : IBA
  7. anastrozole (Arimidex) : 2 outcomes in 2 results : FDA 15 Generic
  8. Deferoxamine (Desferal) : 1 outcome 3 studies in 16 results : FDA 5 Generic
  9. Glutathione (Reduced Glutathione) : 1 outcome 1 study in 3 results : IBA
  10. Interferons : 1 outcome in 8 results : IBA
Show All >>

Diseases Related to Porphyria Cutanea Tarda

  1. Porphyrias
  2. Erythropoietic Protoporphyria
  3. Iron Overload
  4. Infection
  5. Urticaria (Hives)
Show All >>

Key Therapies for Porphyria Cutanea Tarda

Efficacy Chart >>
  1. Renal Dialysis (Hemodialysis) : 2 outcomes in 38 results
  2. Amputation : 1 outcome in 1 result
  3. Blood Transfusion (Blood Transfusions) : 1 study in 3 results
  4. Transplants (Transplant) : 9 results
  5. Aftercare (After-Treatment) : 7 results
Show All >>

CureHunter Inc. provides medical information and specifically does NOT provide medical advice.
© Copyright 2003-2016 CureHunter Inc., MeSH copyright NLM, Journal Articles copyright original owners.